Bankrupt DNA Company 23andMe Expected to Be Purchased for $256M: What Users Need to Know About Their Privacy

Bankrupt 23andMe Expected to Be Purchased for $256M

DNA testing company 23andMe, which filed for bankruptcy in March 2025, is set to be acquired by Regeneron Pharmaceuticals for $256 million. The announcement of the purchase was made by both companies, assuring users that Regeneron is committed to upholding 23andMe’s privacy policies if the sale is approved. This acquisition comes just months after 23andMe laid off approximately 200 employees. The transaction is expected to finalise in the third quarter of 2025 pending approvals from the bankruptcy court and regulatory authorities.

Despite facing financial woes, 23andMe stated that all consumer genome services will continue without interruption under Regeneron’s ownership. The agreement includes a provision for Regeneron to uphold 23andMe’s privacy policies and adhere to relevant laws to safeguard user data. Mark Jensen, Chair of the Board of Directors at 23andMe, expressed gratitude towards Regeneron for offering continued employment to all employees affected by the acquisition. This move ensures that 23andMe’s mission of facilitating health benefits through genetic insights will endure.

Regeneron Pharmaceuticals, the prospective buyer, emphasised their expertise in managing large-scale data and their commitment to supporting 23andMe’s mission. With a focus on utilising genetics research to enhance healthcare outcomes, Regeneron aims to leverage 23andMe’s consumer DNA services for broader societal health improvements. The strategic alignment between the companies signals a positive step towards advancing personalised healthcare options for consumers.

Following the bankruptcy filing, 23andMe initiated Chapter 11 proceedings to facilitate the sale process and optimise the company’s value. Co-founder Anne Wojcicki stepped down as CEO amidst the organisational restructuring. Despite recent challenges, Wojcicki remains optimistic about the future of 23andMe and its potential to continue empowering individuals through genetic understanding. The company’s commitment to safeguarding customer data remains unwavering despite transitions in leadership and ownership.

23andMe’s decision to file for bankruptcy was influenced by various factors, including workforce reductions and a security breach affecting millions of customers. The acquisition by Regeneron represents a pivotal moment in 23andMe’s evolution, promising stability and continuity for its genetic testing services. Regeneron’s assurance to honour 23andMe’s privacy standards underscores a commitment to ethical data management and user protection in the genomics industry.

In conclusion, the impending acquisition of 23andMe by Regeneron Pharmaceuticals marks a significant development in the genetic testing landscape. As the companies move towards finalising the sale, stakeholders can expect a seamless transition that prioritises user privacy and data security. The collaboration between Regeneron and 23andMe holds promise for advancing genetic research and enhancing personalised healthcare options for individuals. Amidst industry shifts and operational changes, the core mission of empowering consumers through genetic insights remains at the forefront of this acquisition deal.